200 related articles for article (PubMed ID: 29942496)
1. Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience.
Bagchi S; Subbiah AK; Bhowmik D; Mahajan S; Yadav RK; Kalaivani M; Singh G; Dinda A; Kumar Agarwal S
Clin Kidney J; 2018 Jun; 11(3):337-341. PubMed ID: 29942496
[TBL] [Abstract][Full Text] [Related]
2. Combination of ultra-low dose rituximab and low dose tacrolimus versus tacrolimus alone in the treatment of non-responsive idiopathic membranous nephropathy: a Chinese retrospective cohort study.
Zhu F; Chu X; Guo Y; Li Y; Cao C; Wu J; Xu H; Deng X; Li J; Liu X; Yao Y; Zeng R
Am J Transl Res; 2021; 13(7):7622-7631. PubMed ID: 34377239
[TBL] [Abstract][Full Text] [Related]
3. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study.
Yan P; Fang X; Ke B
Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859
[TBL] [Abstract][Full Text] [Related]
4. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
[TBL] [Abstract][Full Text] [Related]
5. Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
Chen X; Jiao S; Li S; Li J; Li P; Song F; Yan Z
Balkan Med J; 2023 Jul; 40(4):287-293. PubMed ID: 37260416
[TBL] [Abstract][Full Text] [Related]
6. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.
Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH
Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience.
Wang YW; Wang XH; Wang HX; Yu RH
World J Clin Cases; 2023 Jan; 11(3):566-575. PubMed ID: 36793628
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.
Fervenza FC; Abraham RS; Erickson SB; Irazabal MV; Eirin A; Specks U; Nachman PH; Bergstralh EJ; Leung N; Cosio FG; Hogan MC; Dillon JJ; Hickson LJ; Li X; Cattran DC;
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2188-98. PubMed ID: 20705965
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort.
Wang X; Cui Z; Zhang YM; Qu Z; Wang F; Meng LQ; Cheng XY; Liu G; Zhou FD; Zhao MH
Nephrol Dial Transplant; 2018 Sep; 33(9):1558-1563. PubMed ID: 29149305
[TBL] [Abstract][Full Text] [Related]
10. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.
Kong WY; Swaminathan R; Irish A
Int Urol Nephrol; 2013 Jun; 45(3):795-802. PubMed ID: 22798030
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in patients with membranous nephropathy and kidney insufficiency.
Guo Y; Wang L; Wang Y; Li X; Zhai Z; Yu L; Liang Y; Liu P; Tang L
Front Pharmacol; 2022; 13():1002117. PubMed ID: 36299887
[No Abstract] [Full Text] [Related]
13. Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.
Chen P; Mao M; Wang C; Zhang X; Zhao X; Gao Y; Luo Y; Zhou Y
Front Endocrinol (Lausanne); 2023; 14():1044782. PubMed ID: 36875477
[TBL] [Abstract][Full Text] [Related]
14. Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A
Ma Q; Li M; Xu G
Clin Exp Med; 2023 Dec; 23(8):5337-5343. PubMed ID: 37688683
[TBL] [Abstract][Full Text] [Related]
15. A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up.
Zhou XJ; Zhou FD; Wang SX; Zhao MH
Medicine (Baltimore); 2018 Jun; 97(25):e11184. PubMed ID: 29924035
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in idiopathic membranous nephropathy.
Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G
J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
[TBL] [Abstract][Full Text] [Related]
18. Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis.
Zou PM; Li H; Cai JF; Chen ZJ; Li C; Li XW
Chin Med Sci J; 2018 Mar; 33(1):9-19. PubMed ID: 29620510
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels.
Xue C; Wang J; Pan J; Liang C; Zhou C; Wu J; Song S; Cui L; Zhang L; Liu Y; Dai B
BMC Nephrol; 2023 Sep; 24(1):280. PubMed ID: 37740193
[TBL] [Abstract][Full Text] [Related]
20. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
Moroni G; Depetri F; Del Vecchio L; Gallelli B; Raffiotta F; Giglio E; Brunini F; D'Amico M; Longhi S; Radice A; Messa P; Sinico RA
Nephrol Dial Transplant; 2017 Oct; 32(10):1691-1696. PubMed ID: 27387472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]